“We are delighted to be working with Nzomics. They have identified and cloned genes, encoding a range of enzymes for biocatalytic synthesis to be used in the field of chiral pharmaceutical intermediates – successfully adding to Almac’s growing proprietary enzyme collection.”

Dr Tom Moody, New Technology Team Leader, Almac Sciences

“Prozomix have used Nzomics on numerous occasions and each time received impressive customer support and rapid turnaround enabling new products to be developed within exacting deadlines. Nzomics have also successfully delivered specific enzyme activities requested by Prozomix on a royalty basis arrangement.”

Dr Simon Charnock, Managing Director, Prozomix